-
Clinical Trials & Development2 weeks agoAlzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial
A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer's disease and was well tolerated in a Phase I trial....
-
Clinical Trials & Development2 weeks agoBlood Sugar Spike Plus Frailty Flags Fivefold Death Risk in Heart Patients
A study of 5,580 ICU patients with coronary heart disease shows that combining the stress hyperglycemia ratio with a laboratory-based frailty index identifies a subgroup facing...
-
Clinical Trials & Development2 weeks agoJ&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase...
-
Clinical Trials & Development2 weeks agoBeyond patient matching: AI’s role in reshaping trial recruitment
BIOCENTURY | PRODUCT DEVELOPMENTBEYOND PATIENT MATCHING: AI’S ROLE IN RESHAPING TRIAL RECRUITMENTTriNetX, Paradigm, and Tempus tackle feasibility, enrollment workflows, and site activation through different models
-
Clinical Trials & Development2 weeks agoBioNTech sticks with cancer vaccine despite trial miss
BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
-
Clinical Trials & Development2 weeks agoBioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out...
-
Clinical Trials & Development2 weeks agoChina’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all...
-
Clinical Trials & Development2 weeks agoProteomic aging clocks go to trial
Nature Biotechnology, Published online: 13 October 2026; doi:10.1038/s41587-026-03361-4Six proteomic aging clocks are deployed in a clinical trial for the first time, revealing more about the clocks...
-
Clinical Trials & Development2 weeks agoSTAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.
-
Clinical Trials & Development3 weeks agoBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
PRINCETON, N.J.--(BUSINESS WIRE) October 12, 2026 -- Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
